

## KNOWLEDGE SHARING AND CAPACITY BUILDING

- The *return of in-person* format entailed Q&A with discussion, face-to-face networking, and building relationships with vendors.
- Premiere of *roundtable discussions* created the opportunity to focus on specific topics in-depth and sparked lively discussions.
- Introduction of *gene editing and supply chain* sessions.
- *Additional discussion time* in the AAV and Potency session prompted active participation from the audience in these discussions.

## Cell & Gene Therapy Products 2022 BY THE NUMBERS



### Attendee Participants

In-Person - **163**

Virtual - **201**

First Time - **185**



### Regulators Participation

**21**



### Company Participation

**102**



### Country Participation

**21**

Austria | Belgium | Brazil | Canada | Czech Republic | Denmark |  
Finland | France | Germany | India | Israel | Italy | Japan |  
Netherlands | Portugal | Singapore | Spain | Sweden |  
Switzerland | United Kingdom | United States